Drug Information
| Drug General Information | |||||
|---|---|---|---|---|---|
| Drug ID |
D0Z6DE
|
||||
| Former ID |
DCL000967
|
||||
| Drug Name |
RPSGL-Ig
|
||||
| Indication | Delayed graft function; Heart transplantation [ICD9: 996; ICD10:T86] | Phase 2 | [537129] | ||
| Company |
Thios Pharmaceuticals
|
||||
| Target and Pathway | |||||
| Target(s) | P-selectin | Target Info | Inhibitor | [533194], [537129] | |
| Pathway Interaction Database | IL4-mediated signaling events | ||||
| amb2 Integrin signaling | |||||
| References | |||||
| Ref 533194 | rPSGL-1-Ig, a recombinant PSGL-1-Ig fusion protein, ameliorates LPS-induced acute lung injury in mice by inhibiting neutrophil migration. Cell Mol Biol (Noisy-le-grand). 2015 Feb 28;61(1):1-6. | ||||
| Ref 537129 | New developments in immunosuppressive therapy for heart transplantation. Expert Opin Emerg Drugs. 2009 Mar;14(1):1-21. | ||||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Tang and Dr. Zhang.